Comparative Pharmacology
Head-to-head clinical analysis: SINOGRAFIN versus TELEPAQUE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: SINOGRAFIN versus TELEPAQUE.
SINOGRAFIN vs TELEPAQUE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Non-ionic iodinated contrast agent that attenuates X-rays, providing radiographic contrast by enhancing the differential absorption between vascular structures and surrounding tissues. It distributes into the extracellular fluid space and is excreted renally.
Telepaque (iopanoic acid) is an oral cholecystographic agent. It is absorbed from the gastrointestinal tract, conjugated in the liver, and excreted in bile. In the gallbladder, it concentrates and opacifies the bile, allowing radiographic visualization. It is also a non-competitive inhibitor of 5'-deiodinase, reducing conversion of T4 to T3.
Intravenous or intra-arterial administration; typical adult dose for CT urography: 50-100 mL of a 30% solution; for pyelography: 25-50 mL of a 30% solution; dose based on procedure and patient size, not to exceed 5 mL/kg.
3 to 6 g orally as a single dose administered 10-14 hours before cholecystography, typically as 6 to 12 tablets (500 mg each).
None Documented
None Documented
Terminal elimination half-life: 1.5–2.5 hours in patients with normal renal function; prolonged in renal impairment (up to 20 hours). Context: rapid clearance allows for repeated dosing in diagnostic imaging.
Terminal elimination half-life is approximately 8-12 hours; may be prolonged in patients with renal impairment or biliary obstruction.
Renal excretion of intact drug via glomerular filtration; approximately 90% eliminated unchanged in urine within 24 hours; less than 5% fecal elimination.
Primarily renal (90-95% within 24 hours, via glomerular filtration without significant tubular reabsorption); fecal excretion accounts for <5% as unchanged drug.
Category C
Category C
Radiocontrast agent
Radiocontrast agent